WCH Stock Analysis: Wacker Chemie | XETRA
Specialty Chemicals | XETRA, Germany | Market Cap: 4.516m EUR | 12M Return: 52.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.53M
Qual. Beats: 0
Rev. Trend: -90.9%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Wacker Chemie AG is a Munich-based specialty chemicals company founded in 1914, operating four business segments: Silicones, Polymers, Biosolutions, and Polysilicon. Its product portfolio spans silicone fluids, elastomers and resins, dispersible polymer powders, pharmaceutical proteins and cyclodextrins, and hyperpure polysilicon, serving end-markets including automotive, construction, semiconductors, medical technology, pharmaceuticals, and photovoltaics. The company is family-controlled, operating as a subsidiary of Dr. Alexander Wacker Familiengesellschaft mbH, and exports globally from its European base to Asia and the Americas.
The business model is diversified across several cyclical industries, which provides some balance but also exposes results to swings in construction, automotive demand, and the photovoltaic supply chain. Its polysilicon segment ties the company closely to the solar and semiconductor value chains, where hyperpure silicon is a critical upstream input, while the silicones and polymers segments supply formulation ingredients used by downstream manufacturers in construction, personal care, and industrial coatings.
- Polysilicon prices pressured by Chinese solar oversupply
- Semiconductor-grade polysilicon demand offsets solar weakness
- German energy costs continue squeezing silicones and polymers margins
| Net Income: -797.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA 7.86 > 1.0 |
| NWC/Revenue: 49.09% < 20% (prev 43.75%; Δ 5.34% < -1%) |
| CFO/TA 0.07 > 3% & CFO 588.4m > Net Income -797.9m |
| Net Debt (1.22b) to EBITDA (450.3m): 2.71 < 3 |
| Current Ratio: 2.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (72.9m) vs 12m ago 47.56% < -2% |
| Gross Margin: 12.68% > 18% (prev 16.95%; Δ -4.27% > 0.5%) |
| Asset Turnover: 61.45% > 50% (prev 62.60%; Δ -1.15% > 0%) |
| Interest Coverage Ratio: -0.16 > 6 (EBIT TTM -45.8m / Interest Expense TTM 278.7m) |
| A: 0.31 (Total Current Assets 3.99b - Total Current Liabilities 1.34b) / Total Assets 8.50b |
| B: 0.39 (Retained Earnings 3.28b / Total Assets 8.50b) |
| C: -0.01 (EBIT TTM -45.8m / Avg Total Assets 8.81b) |
| D: 0.78 (Book Value of Equity 3.65b / Total Liabilities 4.68b) |
| Altman-Z'' = 4.09 = AA |
| DSRI: 1.21 (Receivables 1.01b/880.3m, Revenue 5.41b/5.71b) |
| GMI: 1.34 (GM 16.95% / 12.68%) |
| AQI: 0.63 (AQ_t 0.12 / AQ_t-1 0.18) |
| SGI: 0.95 (Revenue 5.41b / 5.71b) |
| TATA: -0.16 (NI -797.9m - CFO 588.4m) / TA 8.50b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of July 06, 2026, the stock is trading at EUR 95.15 with a total of 73,280 shares traded. Over the past week, the price has changed by +3.09%, over one month by -2.96%, over three months by +12.95% and over the past year by +52.30%.
Current recommended Stop Loss: 90.90 (which is 4.5% or 1.3 ATR below the current price).
Wacker Chemie has no consensus analysts rating.
P/E Forward = 21.9298
P/S = 0.8343
P/B = 1.2123
P/EG = 5.1721
Revenue TTM = 5.41b EUR
EBIT TTM = -45.8m EUR
EBITDA TTM = 450.3m EUR
Long Term Debt = 1.93b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 161.8m EUR (from shortTermDebt, last fiscal year)
Debt = 2.73b EUR (from shortLongTermDebtTotal, last quarter) + Leases 323.0m
Net Debt = 1.22b EUR (calculated: Debt 2.73b - CCE 1.51b)
Enterprise Value = 5.74b EUR (4.52b + Debt 2.73b - CCE 1.51b)
Interest Coverage Ratio = -0.16 (Ebit TTM -45.8m / Interest Expense TTM 278.7m)
EV/FCF = 162.9x (Enterprise Value 5.74b / FCF TTM 35.2m)
FCF Yield = 0.61% (FCF TTM 35.2m / Enterprise Value 5.74b)
FCF Margin = 0.65% (FCF TTM 35.2m / Revenue TTM 5.41b)
Net Margin = -14.74% (Net Income TTM -797.9m / Revenue TTM 5.41b)
Gross Margin = 12.68% ((Revenue TTM 5.41b - Cost of Revenue TTM 4.73b) / Revenue TTM)
Gross Margin QoQ = 15.63% (prev 11.73%)
Tobins Q-Ratio = 0.68 (Enterprise Value 5.74b / Total Assets 8.50b)
Interest Expense / Debt = 10.22% (Interest Expense 278.7m / Debt 2.73b)
Taxrate = 40.47% (10.4m / 25.7m)
NOPAT = -27.3m (EBIT -45.8m * (1 - 40.47%)) [loss with tax shield]
Current Ratio = 2.99 (Total Current Assets 3.99b / Total Current Liabilities 1.34b)
Debt / Equity = 0.75 (Debt 2.73b / totalStockholderEquity, last quarter 3.65b)
Debt / EBITDA = 2.71 (Net Debt 1.22b / EBITDA 450.3m)
Debt / FCF = 34.65 (Net Debt 1.22b / FCF TTM 35.2m)
Total Stockholder Equity = 3.97b (last 4 quarters mean from totalStockholderEquity)
RoA = -9.06% (Net Income -797.9m / Total Assets 8.50b)
RoE = -20.12% (Net Income TTM -797.9m / Total Stockholder Equity 3.97b)
RoCE = -0.78% (EBIT -45.8m / Capital Employed (Equity 3.97b + L.T.Debt 1.93b))
RoIC = -0.39% (negative operating profit) (NOPAT -27.3m / Invested Capital 7.05b)
WACC = 7.13% (E(4.52b)/V(7.24b) * Re(7.76%) + D(2.73b)/V(7.24b) * Rd(10.22%) * (1-Tc(0.40)))
Discount Rate = 7.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 4.60 | Cagr: 18.55%
[DCF] Terminal Value 75.44% ; FCFF base≈35.2m ; Y1≈35.3m ; Y5≈37.4m
[DCF] Fair Price = N/A (negative equity: EV 582.3m - Net Debt 1.22b = -637.4m; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.06 | # QB: 0
Revenue Correlation: -90.86 | Revenue CAGR: -9.32% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.14 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.02 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-12-31): EPS=0.65 | Chg30d=-9.35% | Revisions=+38% | GrowthEPS=+110.4% | GrowthRev=+4.7%
EPS next Year (2027-12-31): EPS=2.41 | Chg30d=+1.00% | Revisions=+0% | GrowthEPS=+272.3% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: +21% (up=7, down=4)